

09/526,855

Page 1

=> d ibib ab hitstr 1-7

3/24/04

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:211446 CAPLUS
 DOCUMENT NUMBER: 137:28399
 TITLE: CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogesterins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914
 AUTHOR(S): Attardi, Barbara J.; Burgenson, Janet; Hild, Sheri A.; Reel, Jerry R.; Blye, Richard P.
 CORPORATE SOURCE: Molecular Endocrinology Laboratory, BIOQUAL, Inc., Rockville, MD, 20850, USA
 SOURCE: Molecular and Cellular Endocrinology (2002), 188(1-2), 111-123
 CODEN: MCEND6; ISSN: 0303-7207
 PUBLISHER: Elsevier Science Ireland Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB To obtain selective antiprogesterins, we have examd. the in vitro antiprogesterinal/antiglucocorticoid properties of two novel compds., CDB-4124 and the putative monodemethylated metabolite, CDB-4453, in transcription and receptor binding assays and compared them to CDB-2914 and mifepristone. All four antiprogesterins bound with high affinity to rabbit uterine progesterin receptors (PR) and recombinant human PR-A and PR-B (rhPR-A, rhPR-B) and were potent inhibitors of R5020-induced transactivation of the PRE2-tk-luciferase (PRE2-tk-LUC) reporter plasmid and endogenous alk. phosphatase prodn. in T47D-CO human breast cancer cells. None of these compds. exhibited agonist activity in these cells. Induction of luciferase activity was potentiated about five-fold by 8-Br-cAMP under basal conditions and to the same extent in the presence of the PR antagonists. Mifepristone bound to rabbit thymic glucocorticoid receptors (GR) with approx. twice the avidity of the CDB antiprogesterins. Inhibition of GR-mediated transcription of PRE2-tk-LUC was assessed in HepG2 human hepatoblastoma cells. Mifepristone exhibited greater antiglucocorticoid activity than CDB-2914, 4124, and 4453, about 12-, 22-, and 185-fold, resp. Thus, while there was a good correlation between binding to PR and functional activity of these antiprogesterins, GR binding was not predictive of their glucocorticoid antagonist activity. In agreement with our in vivo results, CDB-4124 and CDB-4453, as well as CDB-2914, are potent antiprogesterins in vitro, but show considerably less antiglucocorticoid activity than mifepristone.
 IT 198414-31-2, CDB-4124 365416-20-0, CDB 4453
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CDB-4124 and putative monodemethylated metabolite, CDB-4453, are potent antiprogesterins with reduced antiglucocorticoid activity in transcription and receptor binding assays)
 RN 198414-31-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:747811 CAPLUS
 DOCUMENT NUMBER: 135:304062
 TITLE: Preparation of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregna-4,9-diene-3,20-dione derivatives as new antiprogesterinal agents
 INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.; Cessac, James W.; Acosta, Carmie K.; Simmons, Anne Marie
 PATENT ASSIGNEE(S): Secretary of Health and Human Services, USA
 SOURCE: PCT Int. Appl., 171 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074840	A2	20011011	WO 2001-US8681	20010316
WO 2001074840	A3	20020502		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 2001045849 A5 20011015 AU 2001-45849 20010316
 EP 1265911 A2 20021218 EP 2001-918812 20010316
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003529004 T2 20031007 JP 2001-572529 20010316
 PRIORITY APPLM. INFO.: US 2000-526855 A 20000317
 WO 2001-US8681 W 20010316


OTHER SOURCE(S): MARPAT 135:304062
 AB 19-Norpregna-4,9-diene-3,20-dione derivs. [1] R1 = OMe, SMe, NMe2, NMe, NC4H8, NC5H10, NC4H8O, CHO, CH(OH)Me, C(O)Me, O(CH2)2NMe2, and -O(CH2)2NCSH10; R2 = H, halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkylcarbonate, cyponyloxy, S-alkyl, -SCN, S-acyl and -OC(O)R6; R6 = alkyl, alkoxy ester, alkoxy; R3 = alkyl, hydroxy, alkoxy and acyloxy; R4 = H, alkyl; X = O, (substituted) NOH were prepd as antiprogesterinal agents. The present invention provides methods wherein i were advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception. Thus, norpregnadienedione deriv. 17 was prepd. from 3,3-ethylenedioxy-17.beta.-cyano-17.alpha.-hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps which showed 2.79 times the antiprogesterinal potency in the antiClauberg test compared to CDB-2914.
 IT 198414-09-4P, CDB 4102 198414-31-2P, CDB 4124
 198414-39-0P, CDB 4167 365416-60-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 365416-28-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 [prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogesterinal agents]
 RN 198414-09-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-31-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-39-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-60-0 CAPLUS

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dimethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 198414-03-8P, CDB 4058 198414-05-0P, CDB 3976
 198414-07-2P, CDB 4059 198414-11-8P, CDB 4101
 198414-22-1P, CDB 4030 198414-33-4P, CDB 4125
 198414-34-5P, CDB 4152 198414-41-4P 198414-43-6P
 , CDB 4031 365415-80-1P 365416-26-8P
 365416-28-0P 365416-58-6P 365416-61-1P
 365416-62-2P 365416-63-3P 365416-64-4P
 365416-67-7P 365416-68-8P 365416-69-9P
 365416-70-2P 365416-71-3P 365416-72-4P
 365416-73-5P 365416-74-6P 365416-75-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogesterational agents)

RN 198414-03-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-05-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry. Rotation (+).




RN 198414-33-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-34-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-41-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Absolute stereochemistry.




RN 198414-07-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-11-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(acetylthio)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-22-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 198414-43-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365415-80-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 365416-26-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dimethoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry unknown.




RN 365416-28-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-58-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 365416-64-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-methoxy-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-67-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-68-8 CAPLUS

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 365416-61-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-ethoxy-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-62-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-dimethoxy-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-63-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-dimethoxy-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-[(methoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-69-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-[(methoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-70-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-(ethenoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 365416-71-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-(ethenyloxy)-17-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-72-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-(ethenyloxy)-17-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-73-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-thiocyanato-, (11.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

IT 198413-96-6P 198413-97-7P 198413-98-8P
198413-99-9P 198414-00-5P 198414-21-0P
198414-30-1P 198414-32-3P 198414-38-9P
198414-42-5P 365416-07-5P 365416-08-6P
365416-17-7P 365416-18-8P 365416-19-9P
365416-20-2P 365416-21-3P 365416-22-4P
365416-48-4P 365416-49-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogesterone agents)


RN 198413-96-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-chloro-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198413-97-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198413-98-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.


RN 365416-74-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-bis(formyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-75-7 CAPLUS
CN Glycine, N,N-dimethyl-, (11.beta.)-17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-3,20-dioxo-19-norpregna-4,9-dien-21-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 198413-99-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-00-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-fluoro-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-21-0 CAPLUS
CN Extra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 198414-30-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-32-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-38-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-ethoxy-

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 365416-08-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-hydroxy-11-[4-(1-piperidinyl)phenyl]-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-17-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-hydroxy-21-methoxy-11-[4-(1-piperidinyl)phenyl]-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-18-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-(1-oxopropoxy)-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 198414-42-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365416-07-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-chloro-17-hydroxy-11-[4-(1-piperidinyl)phenyl]-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 365416-19-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-[(chloroacetyl)oxy]-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-20-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-[(chloroacetyl)oxy]-11-[4-(dimethylamino)phenyl]-, (11β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-21-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-


L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(dimethylamino)phenyl]-21-[(iodoacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365416-22-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-thiocyanato-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365416-48-4 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-[(methoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 365416-27-9 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 365416-49-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-[(methoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 365416-23-5P 365416-27-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 17.alpha.-substituted-11.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents)
RN 365416-23-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-(formyloxy)-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:489415 CAPLUS
DOCUMENT NUMBER: 135:61476
TITLE: Process for the preparation of 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
INVENTOR(S): Kim, Hyun Koo; Rao, Pemmaraju N.; Cessac, James W.; Simmons, Anne Marie
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047945	A1	20010705	WO 2000-0535479	20001229
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, ND, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RW, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001026048	A5	20010709	AU 2001-26048	20001229
EP 1242444	A1	20020925	EP 2000-989551	20001229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003060646	A1	20030327	US 2002-169139	20020627
PRIORITY APPLN. INFO.: US 1999-173470P P 19991229				
WO 2000-0535479 W 20001229				

OTHER SOURCE(S): CASREACT 135:61476
AB A process for prep. the antiprogestational agent, 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione (I), intermediates useful in the process, and processes for prep. such intermediates was described. I was prepd. via a multistep synthetic sequence starting from cynaohydrin II. The synthetic sequence involved replacing the cyanohydrin group of II with a chloroacetyl group and a hydroxyl group; replacing the chloro group of the resulting compd. with an acetoxy group; deacetylating the resulting compd.; selectively ketalizing the resulting compd.; selectively methylating the 21-hydroxyl group of the resulting compd.; reducing the 20-keto group of the resulting compd.; epoxidizing the resulting compd.; introducing a N,N-dimethylaminophenyl group at the 11-position and opening the epoxide; deketalizing the resulting compd.; selectively oxidizing the 20-hydroxyl group to a keto group; and acetylating the resulting compd.

IT 198414-30-1
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the prep. of 17.alpha.-acetoxy-11.beta.-[4-N,N-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for prep. such intermediates)
RN 198414-30-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-


L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 198414-31-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for the prepn. of 17.alpha.-acetoxy-11.beta.-(4-N,N-dimethylamino)phenyl-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for prepn. such intermediates)
RN 198414-31-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

328537-10-6P 328537-11-7P 328537-12-8P
328537-25-3P 328537-27-5P 328537-29-7P
328537-31-1P 328537-33-3P 328537-35-5P
328537-48-0P 328537-49-1P 328537-50-4P
328537-51-5P 328537-52-6P 328537-53-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-(cyclic amino)arylsteroids with antiprogesterational activity)


RN 328535-36-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(4-morpholinyl)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328535-37-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(4-morpholinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328535-38-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(4-morpholinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:185774 CAPLUS

DOCUMENT NUMBER: 134:208009

TITLE: Preparation of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-(cyclic amino)aryl steroids and their derivatives having antagonist hormonal properties
Cook, C. Edgar; Kepler, John A.; O'Reilly, Jill M.
Research Triangle Institute, USA
PCT Int. Appl., 70 pp.
CODEN: PIXKD2

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018025	A2	20010315	WO 2000-US24274	20000905
WO 2001018025	A3	20010920		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SO, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000071113	A5	20010410	AU 2000-71113	20000905
EP 1208113	A2	20020529	EP 2000-959867	20000905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, NC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508540	T2	20030304	JP 2001-522248	20000905
NO 2002001037	A	20020405	NO 2002-1037	20020301
PRIORITY APPL. INFO.:			US 1999-389212	A 19990903
			WO 2000-US24274	W 20000905

OTHER SOURCE(S): MARPAT 134:208009

AB The invention is directed to the prepn. of 17.beta.-acyl-17.alpha.-propynyl steroids of formula I [R1 = heterocycle; R2 = Me, CF3, CH2OH; R3 = H, Me, OAc; halo; R4 = H, Me, F, Cl; X = O, H2, NOH, NOME] which exhibit potent antiprogesterational activity. Thus, II was prepd. from 17.beta.-cyano-3,3-(ethanediyldioxy)-17.alpha.-trimethylsilyloxy-5(10),9(11)-diene in 8 steps. The anti-McInty assay for antiprogesterational activity shows II to be an exceptionally potent antiprogesterational agent with a marked effect at 0.3 .mu.g. dose.

IT 328535-36-0P 328535-37-1P 328535-38-2P
328535-39-3P 328535-40-6P 328535-41-7P
328535-54-2P 328535-55-3P 328535-56-4P
328535-57-5P 328535-58-6P 328535-59-7P
328535-89-3P 328535-90-6P 328535-91-7P
328535-92-8P 328535-94-0P 328535-96-2P
328536-20-5P 328536-22-7P 328536-23-8P
328536-24-9P 328536-25-0P 328536-26-1P
328536-56-7P 328536-57-8P 328536-58-9P
328536-59-0P 328536-60-3P 328536-61-4P
328536-74-9P 328536-75-0P 328536-76-1P
328536-77-2P 328536-78-3P 328536-79-4P
328537-07-1P 328537-08-2P 328537-09-3P


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328535-39-3 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(4-morpholinyl)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328535-40-6 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(4-morpholinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 328535-41-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(4-morpholinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 328535-54-2 CAPLUS
 CN Estr-4,9-dien-3-one, 11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328535-55-3 CAPLUS
 CN Estr-4,9-dien-3-one, 11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328535-58-6 CAPLUS
 CN Estr-4,9-dien-3-one, 11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 328535-59-7 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328535-56-4 CAPLUS
 CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328535-57-5 CAPLUS
 CN Estr-4,9-dien-3-one, 11-[4-(4-morpholinyl)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328535-89-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328535-90-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328535-91-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328535-92-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328535-94-0 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328536-22-7 CAPLUS
CN Estradiol-4,9-dien-3-one, 17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-23-8 CAPLUS
CN Estradiol-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-24-9 CAPLUS
CN Estradiol-4,9-dien-3-one, 17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328535-96-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(1-piperidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 328536-20-5 CAPLUS
CN Estradiol-4,9-dien-3-one, 17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 328536-25-0 CAPLUS
CN Estradiol-4,9-dien-3-one, 17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328536-26-1 CAPLUS
CN Estradiol-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-11-[4-(1-piperidinyl)phenyl]-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328536-56-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-17-(1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-57-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-pyrrolidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328536-61-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 328536-74-9 CAPLUS
 CN Estradien-3-one, 17-(1-oxopropyl)-17-(1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-75-0 CAPLUS
 CN Estradien-3-one, 17-(1-oxopropyl)-11-[4-(1-pyrrolidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 328536-58-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-59-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-17-(1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 328536-60-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(1-pyrrolidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328536-76-1 CAPLUS
 CN Estradien-3-one, 17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 328536-77-2 CAPLUS
 CN Estradien-3-one, 17-(1-oxopropyl)-17-(1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 328536-78-3 CAPLUS
 CN Estradien-3-one, 17-(1-oxopropyl)-11-[4-(1-pyrrolidinyl)phenyl]-17-


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 328536-79-4 CAPLUS
CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328537-07-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(4-morpholinyl)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328537-10-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(4-morpholinyl)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 328537-11-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(4-morpholinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328537-08-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(4-morpholinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328537-09-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(4-morpholinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328537-12-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(4-morpholinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 328537-25-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 328537-27-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328537-29-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(1-piperidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328537-31-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 328537-33-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-piperidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 328537-35-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(1-piperidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 328537-48-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 328537-49-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-pyrrolidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 328537-50-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 328537-51-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 328537-52-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(1-pyrrolidinyl)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 328537-53-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[4-(1-pyrrolidinyl)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:401850 CAPLUS
 DOCUMENT NUMBER: 133:17687
 TITLE: Preparation of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
 INVENTOR(S): Cook, C. Edgar; Kepler, John A.; O'Reilly, Jill M.
 PATENT ASSIGNEE(S): Research Triangle Institute, USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000034306	A1	20000615	WO 1999-US28535	19991203
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AT, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6172052	B1	20010109	US 1998-205395	19981204
CA 2358466	AA	20000615	CA 1999-2358466	19991203
EP 1135403	A1	20010926	EP 1999-964047	19991203
EP 1135403	B1	20030730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 512697	A	20030131	NZ 1999-512697	19991203
AT 246201	E	20030815	AT 1999-964047	19991203
PT 1135403	T	20031231	PT 1999-99964047	19991203
PRIORITY APPLN. INFO.: US 1998-205395 A 19981204 WO 1999-US28535 W 19991203				


OTHER SOURCE(S): MARPAT 133:17687
 AB Novel 17.beta.-acyl-17.alpha.-propynyl steroids of formula I [R1 = NMe2, NMe, NH2; R2 = Me, CF3, CH2OH; R3 = H, Me, OMe, OAc; R4 = H, Me, F, Cl; X = O, H2, NOH, NOME] are prep. which exhibit potent antiprogesterone activity. Thus, I was prep. from estrone in many steps. The relative progesterone binding activity of II was 3131 of promegestone.
 IT 273208-59-6P 273208-60-9P 273208-61-0P
 273208-62-1P 273208-63-2P 273208-64-3P
 273208-77-8P 273208-78-9P 273208-79-0P
 273208-80-3P 273208-81-4P 273208-82-5P
 273209-12-4P 273209-13-5P 273209-14-6P
 273209-15-7P 273209-16-8P 273209-17-9P
 273209-30-6P 273209-31-7P 273209-32-8P
 273209-33-9P 273209-34-0P 273209-35-1P
 273209-67-9P 273209-68-0P 273209-69-1P
 273209-70-4P 273209-71-5P 273209-72-6P
 273209-85-1P 273209-86-2P 273209-87-3P
 273209-88-4P 273209-89-5P 273209-90-8P
 273210-18-7P 273210-19-8P 273210-20-1P

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

273210-21-2P 273210-22-3P 273210-23-4P
 273210-36-9P 273210-37-0P 273210-38-1P
 273210-39-2P 273210-40-5P 273210-41-6P
 273210-54-1P 273210-55-2P 273210-56-3P
 273210-57-4P 273210-58-5P 273210-59-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids with antiprogesterone activity)


RN 273208-59-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273208-60-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273208-61-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 273208-62-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 273208-63-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 273208-64-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-21-methoxy-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 273208-77-8 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273208-78-9 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273208-79-0 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 273208-82-5 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273209-12-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-13-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 273209-14-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.


RN 273208-80-3 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273208-81-4 CAPLUS
 CN Estradiol-4,9-dien-3-one, 11-(4-aminophenyl)-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
hydroxy-1-propynyl)-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-15-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 273209-16-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-methoxy-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 273209-17-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-(3-


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 hydroxy-1-propynyl)-21-methoxy-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 273209-30-6 CAPLUS
 CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-31-7 CAPLUS
 CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 273209-35-1 CAPLUS
 CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 273209-67-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273209-68-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 273209-32-8 CAPLUS
 CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-33-9 CAPLUS
 CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 273209-34-0 CAPLUS
 CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 273209-69-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-[4-(methylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-70-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 273209-71-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-methoxy-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 273209-72-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 17-(3-hydroxy-1-propynyl)-21-methoxy-11-(4-(methylamino)phenyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 273209-85-1 CAPLUS
CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273209-86-2 CAPLUS
CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 273209-90-8 CAPLUS
CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 273210-18-7 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-19-8 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.




RN 273209-87-3 CAPLUS
CN Estr-4,9-dien-3-one, 17-(3-hydroxy-1-propynyl)-11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273209-88-4 CAPLUS
CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 273209-89-5 CAPLUS
CN Estr-4,9-dien-3-one, 11-[4-(methylamino)phenyl]-17-(1-oxopropyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-20-1 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 273210-21-2 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 273210-22-3 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-(4-aminophenyl)-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Absolute stereochemistry.
 Double bond geometry unknown.




RN 273210-23-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(aminophenyl)-17-(3-hydroxy-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 273210-36-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 273210-40-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 273210-41-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 273210-54-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 273210-37-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-38-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273210-39-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Absolute stereochemistry.




RN 273210-55-2 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273210-56-3 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(3-hydroxy-1-propynyl)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 273210-57-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(methylamino)phenyl]-17-(1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Double bond geometry unknown.




RN 273210-58-5 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[(4-methylamino)phenyl]-17-(3,3,3-trifluoro-1-propynyl)-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 273210-59-6 CAPLUS
CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-17-(3-hydroxy-1-propynyl)-11-[(4-methylamino)phenyl]-, 3-oxime, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:576939 CAPLUS
DOCUMENT NUMBER: 131:199885
TITLE: Preparation of 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
INVENTOR(S): Cook, C. Edgar; Kepler, John A.; Zhang, Ping-sheng; Lee, Yue-wei; Tallent, C. Ray
PATENT ASSIGNEE(S): Research Triangle Institute, USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945022	A1	19990910	WO 1999-US3732	19990305
V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, YU, ZA, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6020328	A	20000201	US 1998-35949	19980306
CA 2322862	AA	19990910	CA 1999-2322862	19990305
AU 9928715	A1	19990920	AU 1999-28715	19990305
AU 767660	B2	20031120		
EP 1060186	A1	20001220	EP 1999-909531	19990305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9908598	A	20011002	BR 1999-8598	19990305
JP 2002505334	T2	20020219	JP 2000-534564	19990305
PRIORITY APPLN. INFO.: US 1998-35949 A 19980306 WO 1999-US3732 W 19990305				

OTHER SOURCE(S): MARPAT 131:199885
AB 20-Keto-11.beta.-arylsteroids of formula I [X = O, (substituted) NOH, H2, OH, etc.; R1 = dialkylamino, imidazolyl, pyrrolyl, piperidino, etc.; R2 = H, halo; R3 = H, Me, halo; R4 = H, acyloxy, (substituted) OH, alkyl, etc.; R5 = H, alkyl, halo, acyloxy, etc.] are prepd. which exhibit potent antiprogesterational activity. Thus, II was prepd. from 17.alpha.-hydroxymethyl-3-methoxy-19-norpregna-1,3,5(10)-trien-20-one and 4-bromo-N,N-dimethylaniline in several steps. The affinity of II for the progesterone hormone receptor was IC50 of 0.7 nM.
IT 240806-28-4P
AL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 20-keto-11.beta.-arylsteroids with antiprogesterational activity)
RN 240806-28-4 CAPLUS
CN 19,21-Dinorchola-4,9-dien-24-oic acid, 11-[(4-(dimethylamino)phenyl)-17-hydroxy-3,20-dioxo-, ethyl ester, (11.beta.)-], trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 240806-27-3
CMF C32 H41 N O5

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:740250 CAPLUS

DOCUMENT NUMBER: 127:358992

TITLE: Preparation of 21-substituted progesterone derivatives as new antiprogesterone agents

INVENTOR(S): Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;

Cessac, James W.; Acosta, Carmie K.

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA;

Kim, Hyun K.; Blye, Richard P.; Rao, Pemmaraju N.;

Cessac, James W.; Acosta, Carmie K.

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741145	A1	19971106	WO 1997-US7373	19970430
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BO, CF, CO, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253673	AA	19971106	CA 1997-2253673	19970430
AU 9729304	A1	19971119	AU 1997-29304	19970430
AU 710139	B2	19990916		
EP 900234	A1	19990310	EP 1997-923583	19970430
EP 900234	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 194358	E	20000715	AT 1997-923523	19970430
JP 20000509396	T2	20000725	JP 1997-539232	19970430
ES 2152671	T7	20010204	ES 1997-923523	19970430
US 2002025951	A1	20020228	US 999-180132	19990824
GR 3034562	A3	20010131	GR 2000-402252	20001104
PRIORITY APPLN. INFO.: US 1996-16628P P 19960501				
WO 1997-US7373 W 19970430				

OTHER SOURCE(S):


MARPAT 127:358992

AB Progesterone derivs. of formula I [R1 = OMe, SMe, NMe2, NHMe, CHO, Ac, CHOHCH3; R2 = halo, alkyl, acyl, OH, alkoxy, etc.; R3 = OH, alkyl, alkoxy, acyl; R4 = H, alkyl; X = O, (substituted) NOH] are prepd. as antiprogesterone agents. The present invention provides methods wherein the compds. of formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception. Thus, II was prepd. from 3,3-ethylenedioxy-17 β .cyano-17 α .hydroxyestra-5(10),9(11)-diene and 4-bromo-N,N-dimethylaniline in 9 steps. II showed 2.79 times the antiprogesterone potency in the antiClauberg test compared to CDB-2914.

IT 198414-07-2P 198414-08-4P 198414-31-2P

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)



IT 198414-03-8P 198414-05-0P 198414-11-8P

198414-22-1P 198414-32-3P 198414-33-4P

198414-34-5P 198414-39-0P 198414-43-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of progesterone derivs. as antiprogesterone agents)

RN 198414-03-8 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-fluoro-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-05-0 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-chloro-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-11-8 CAPLUS

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant of reagent); USES (Uses)

(prepn. of progesterone derivs. as antiprogesterone agents)

RN 198414-07-2 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-09-4 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetylthio)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-31-2 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

(Continued)

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(acetylthio)-11-[4-(dimethylamino)phenyl]-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-22-1 CAPLUS

CN Extra-4,9-dien-3-one, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-(1-oxopropyl)-, (11 β .),17 α .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198414-32-3 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 198414-33-4 CAPLUS

CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-(3-cyclopentyl-1-


L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 oxopropoxy)-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-34-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-39-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-ethoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 198413-97-7 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-(acetyloxy)-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198413-98-8 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198413-99-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 198414-43-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-21-bromo-11-[4-(dimethylamino)phenyl]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198413-96-6P 198413-97-7P 198413-98-8P
 198413-99-9P 198414-00-5P 198414-21-0P
 198414-30-1P 198414-38-9P 198414-42-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of progesterone derivs. as antiprogesterone agents)
 RN 198413-96-6 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-chloro-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 198414-00-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-fluoro-17-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-21-0 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-oxopropyl)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198414-30-1 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 198414-38-9 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 11-[4-(dimethylamino)phenyl]-21-ethoxy-17-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198414-42-5 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 21-bromo-11-[4-(dimethylamino)phenyl]-17-hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 198414-40-3P 198414-41-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of progesterone derivs. as antiprogesterone agents)
 RN 198414-40-3 CAPLUS


L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 19-Norpregna-4,9-diene-3,20-dione, 17,21-bis(acetyloxy)-11-[4-(dimethylamino)phenyl]-, 3-oxime, (3E,11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 198414-41-4 CAPLUS
 CN 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-21-methoxy-, 3-oxime, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




=> d ibib ab fqhit 1-14

L9 ANSWER 1 OF 14 MARPAT COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 138:390583 MARPAT
 TITLE: Skin-lightening agents containing substances which reduce tyrosinase and cosmetics containing the agents
 INVENTOR(S): Sudo, Shigeru
 PATENT ASSIGNEE(S): Mikimoto Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003155222	A2	20030527	JP 2001-351904	20011116
PRIORITY APPLN. INFO.:			JP 2001-351904	20011116

AB Skin-lightening agents contain substances which reduce amt. of tyrosinase of human melanocytes. The substances may be steroids which show antagonistic activity on progesterone/glucocorticoid receptors and may be represented by 1 [R1 = ethynyl, furyl, 3-6 cycloalkyl, Ph, naphthyl, CGH4Ph, C.ltoreq.6 alkyl which may have several unsatd. bond, alkenyl; R2 = Me, Et; R3 = H, (un)substituted alkyl, alkenyl, alkynyl, hydroxyacetyl, carboxyalkoxy, hydroxyalkyl; R4 = H, OH, C.ltoreq.12 alkyl, alkenyl, alkynyl; R5 = .alpha.- or .beta.-H, Me; X = O, syn- or anti-hydroxyimino, C1-45 alkoxyimino; A and B are bonded together to form .alpha.-epoxy group or optional double bond]. Skin-lightening cosmetics contg. the agents are also claimed. Mifepristone significantly decreased amt. of tyrosinase in normal human epidermal melanocytes and the action was effective in the presence of forskolin or .alpha.MSH. A cream contg. mifepristone was also formulated.

MYSTR 1



L9 ANSWER 2 OF 14 MARPAT COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 129:50105 MARPAT
 TITLE: Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviors
 INVENTOR(S): Oberlander, Claude; Piazza, Pier Vincenzo
 PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.; Oberlander, Claude; Piazza, Pier Vincenzo
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826783	A1	19980625	WO 1997-FR2320	19971217
V: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TW				
W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2757400	A1	19980626	FR 1996-15649	19961219
FR 2757400	B1	19991217		
AU 9855632	A1	19980715	AP 1998-55632	19971217
EP 892641	A1	19990127	EP 1997-952078	19971217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1996-15649		19961219		
WO 1997-FR2320		19971217		

AB Glucocorticoid antagonists, except mifepristone, are used as dopamine type II receptor antagonists to treat psychotic or addictive behavior. Thus, 17.beta.-hydroxy-10.beta.-[4-methylphenylmethyl]-17.alpha.-[1-propynyl]estra-4,9(11)-dien-3-one considerably reduced the response to morphine in vivo.

MYSTR 1




L9 ANSWER 1 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)

21 C(O)CH2-OH

G5 = alkenyl<(-12)> (SO G13)
 G7 = O
 MPL: claim 3

L9 ANSWER 2 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)



41 C(O)CH2-OH

G16 = CN
 DER: and pharmaceutically acceptable acid addition salts
 MPL: claim 4
 NTE: substitution is restricted

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 128:188869 MARPAT
 TITLE: Mixed agonists of the progesterone receptor and assays for them
 INVENTOR(S): McDonnell, Donald P.; Wagner, Brandee L.
 PATENT ASSIGNEE(S): Duke University, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805679	A2	19980212	WO 1997-US13754	19970805

W: CA

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1996-232069 19960805
 AB A third class of PR-ligand (i.e. mixed agonist) is identified which induces a progesterone receptor conformation distinct from that induced by a PR agonist or antagonist; the agonists are extra-4,9-dien-3-one derivatives. PR mixed agonists exhibit partial agonist activity which is influenced by cell context. These compds. provide useful pharmacol. profiles for treating progesterone related diseases and/or conditions, such as uterine proliferation from estrogen administration, endometriosis, breast cancer, fibroids, endometrial cancer, and brain meningiomas. The agonists can also be used as contraceptives. Assays are provided to screen for PR mixed agonists. Mol. designs are provided to convert a PR antagonist to a PR mixed agonist.

MSTR 1



L9 ANSWER 3 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)



G10 = NMe2
 MPL: claim 4

L9 ANSWER 4 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 124:22540 MARPAT
 TITLE: Pharmaceutical compositions of antigluccorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal.
 INVENTOR(S): Petit, Francis; Philibert, Daniel; Ulmann, Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 676203	A1	19951011	EP 1995-400764	19950406

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE

FR 2718354 A1 19951013

FR 2718354 B1 19960503

ZA 9502058 A 19960313

CA 2146600 AA 19951009

FI 9501683 A 19951009

AU 9516326 A1 19951019

JP 07278017 A2 19951024


HU 71468 A2 19951128

CN 1116929 A 19960221

PRIORITY APPLN. INFO.: FR 1994-4156 19940408

AB Antigluccorticoid steroids such as mifepristone, onapristone, lilopristone and related steroids are proposed for the prevention or treatment of withdrawal syndromes, either spontaneous or pptrd. by narcotics or mixts. of narcotics. These antigluccorticoids would be useful in the withdrawal from morphinomimetics such as heroin, morphine or methadone as well as cocaine. Pharmacol. activity was demonstrated by the effect of the antigluccorticoids on the stereotypic behavior of mice in response to narcotics. Spontaneous withdrawal syndrome was induced by administration of the opioid antagonist, naloxone. An antiprogesterone activity of the steroids in their action mechanism was eliminated. Results confirmed the involvement of endogenous glucocorticoids in morphine withdrawal since this is inhibited by antigluccorticoids or adrenalectomy.

MSTR 7



L9 ANSWER 4 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)

G9 = 103




G15 = OH
 G16 = OH
 MPL: or pharmaceutically acceptable addition salts or N-oxides
 claim 17

L9 ANSWER 5 OF 14 MARPAT COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 123:218391 MARPAT
 TITLE: Steroids for reducing multidrug resistance to cancer chemotherapeutic agents
 INVENTOR(S): Cohn, Suzanne Bourgeois; Gruel, Donald J.
 PATENT ASSIGNEE(S): Salk Institute for Biological Studies, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517192	A1	19950629	WO 1994-US14624	19941219
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GM, ML, MR, NE, SN, TD, TG				
AU 9514395	A1	19950710	AU 1995-14395	19941219
US 1993-173243 19931222				
WO 1994-US14624 19941219				

PRIORITY APPLN. INFO.:
 AB Certain steroid-like compds. [I; R1 = H; R2 = OR; or R1R2 = :O; R = H, lower alkyl, Me3Si; R3 = H, Me, or absent if double bond or epoxide bridge joins C9 and C10; R4 = OR, C4-18 cyclic org. group contg. O, N, P, or Si; R5 = lower alkyl, Me3Si; R6 = H, OR or C16C17 form a 3-, 5-, 6-, or 7-membered ring; R6 = C(O)CH3, CH(OH)CH3, C(O)CH2OH, (substituted) hydrocarbyl; R9 = H, halo, or absent if double bond or epoxide bridge joins C9 and C10] are capable of inhibiting the P-glycoprotein-associated efflux pump which is considered responsible for multidrug resistance. Chemotherapy can be enhanced by facilitating the accumulation of drug at the target site, with reduced or eliminated competition by the drug efflux system. Thus RU 38486, an anti-progestin, at 5 .mu.M facilitated killing of multidrug-resistant S7CD5 murine thymoma cells by 20 .mu.M puromycin.

MSTR 1B




L9 ANSWER 5 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)
 G13 = 36
 C(O)CH2-OH
 36
 G16 = NH2
 MPL: claim 1

L9 ANSWER 6 OF 14 MARPAT COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 122:296423 MARPAT
 TITLE: Antiglucocorticoid steroids for the treatment of anxiety disorders
 INVENTOR(S): Peeters, Bernardus Wynand Machijs Maria
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504536	A1	19950216	WO 1994-EP2513	19940728
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GM, ML, MR, NE, SN, TD, TG				
AU 9474968	A1	19950228	AU 1994-74968	19940728
AU 687088	B2	19980219		
EP 712311	A1	19960522	EP 1994-924819	19940728
EP 712311	B1	19981007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, JP 09501172 T2 19970204 JF 1995-506200 19940728				
AT 171873 E 19981015 AT 1994-924819 19940728				
ES 2124905 T3 19990216 ES 1994-924819 19940728				
US 5741787 A 19980421 US 1996-581631 19960118				
PRIORITY APPLN. INFO.: EP 1993-202304 19930804 EP 1994-924819 19940728 WO 1994-EP2513 19940728				

AB Antiglucocorticoid steroids are used for the manuf. of a pharmaceutical compn. for the treatment of anxiety disorders. The anxiolytic effect of 11.beta.-(4-dimethylaminophenyl)-17.beta.-hydroxy-17.alpha.-(prop-1-ynyl)-estra-4,9-dien-3-one (RU38486) was demonstrated in animal testing (antagonism of fear-potentiated startle). Prep. and activity (antagonism of stress-induced hyperthermia) of selected steroids of the invention is also described.

MSTR 1




L9 ANSWER 6 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)
 G11 = alkyl<(1-6)> (SO (1-) G12)
 G16 = alkylcarbonyl<(1-5)> (SO (1-) G17)
 G18 = 39
 G11
 39
 G16
 MPL: claim 2

L9 ANSWER 7 OF 14 MARPAT COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 116:35156 MARPAT
 TITLE: Preparation and use of antiprogesteronimetics for
 synchronization of parturition in livestock
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 446124	A2	19910911	EP 1991-400594	19910305
EP 446124	A3	19920527		
R: AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2659233	A1	19910913	FR 1990-2783	19900306
FR 2659233	B1	19940121		
CA 2037549	AA	19910907	CA 1991-2037549	19910305
AU 9172608	A1	19910912	AU 1991-72608	19910305
AU 642975	B2	19931104		
ZA 9101603	A	19920527	ZA 1991-1603	19910305
JP 04211610	A2	19920803	JP 1991-62496	19910305
RU 2037295	C1	19950619	RU 1991-4895041	19910305
CN 1055665	A	19911030	CN 1991-102108	19910306
HU 59006	A2	19920428	HU 1991-729	19910306

PRIORITY APPLN. INFO.: FR 1990-2783 19900306
 AB The title antiprogesteronimetics are I (R1 = C1-18 hydrocarbyl optionally substituted with .gtoreq.1 heteroatoms and bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = remainder of 5- and 6-membered ring optionally substituted and optionally unsatd.; C = A = CNOH, oxo (free or blocked as ketal), etc.; B and C together form a double bond or epoxide bridge) and acid addn. salts thereof. Prepn. of 2 I are described.
 17.beta.-Hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one (II) was more effective at synchronizing parturition than cloprostenol when tested in sows. Injectable pharmaceuticals contg. II are disclosed.

MSTR 1C



G1 = 30

L9 ANSWER 8 OF 14 MARPAT COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 115:214857 MARPAT
 TITLE: Injectable microspheres containing antiestrogenic and
 antiprogesteronimetic steroids
 INVENTOR(S): Cohen, Gerard; Dubois, Jean Luc
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4036425	A1	19910516	DE 1990-4036425	19901115
FR 2654337	A1	19910517	FR 1989-14976	19891115
FR 2654337	B1	19940805		
SE 9003570	A	19910516	SE 1990-3570	19901109
BE 1005511	A4	19930831	BE 1990-1062	19901109
DK 9002709	A	19910516	DK 1990-2709	19901113
CA 2029940	AA	19910516	CA 1990-2029940	19901114
JP 03294229	A2	19911225	JP 1990-306374	19901114
CH 681691	A	19930514	CH 1990-3611	19901114
NL 9002492	A	19910603	NL 1990-2492	19901115
GB 2239798	A1	19910717	GB 1990-24862	19901115
GB 2239798	B2	19931027		
AT 9002313	A	19950415	AT 1990-2313	19901115
AT 400298	B	19951127		

PRIORITY APPLN. INFO.: FR 1989-14976 19891115
 AB Biodegradable microspheres comprise the title steroids (Markush given) and copolymers of lactic acid with glycolic acid. A mixt. of 250 mL aq. 0.3% hydrolyzed PVA soln., 1 g poly(DL-lactic acid-glycolic acid), 17 g CH2Cl2, and 0.5 g 17.beta.-hydroxy-11.beta.-(4-(dimethylamino)phenyl)-17.alpha.-(1-propynyl)estra-4,9-dien-3-one was emulsified, followed by stirring at 22.degree. and decreasing pressure (.gtoreq.400 mm Hg) to give microspheres, which were used for the prepn. of injections.

MSTR 1A


G1-G3

G1 = 3



G3 = 24

L9 ANSWER 7 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)



G3 = 55-13 57-14



G9 = 40




G15 = 61



G17 = 0

DER: and protected derivatives
 DER: and acid addition salts
 MPL: claim 1

L9 ANSWER 8 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)



G5 = 68-26 70-27



G9 = 74



G13 = OH

G16 = 128



MPL: claim 6


L9 ANSWER 9 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 115:151901 MARPAT
 TITLE: Use of antiprogesteronimetics for stimulating ovulation, and new preparation for use in pharmaceutical compositions
 INVENTOR(S): Grandadam, Jean Andre
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 417003	A2	19910313	EP 1990-402449	19900906
EP 417003	A3	19911204		
EP 417003	B1	19940629		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE				
FR 2651435	A1	19910308	FR 1989-11699	19890907
FR 2651435	B1	19940422		
US 5173483	A	19921222	US 1990-578894	19900905
CA 2024728	AA	19910308	CA 1990-2024728	19900906
AU 9062259	A1	19910314	AU 1990-62259	19900907
AU 623805	B2	19920521		
JP 03099015	A2	19910424	JP 1990-236004	19900907
JP 3032258	B2	20000410		

PRIORITY APPLN. INFO.: FR 1989-11699 19890907
 AB Anti-progesteronimetic compds., e.g. I [R1 = C1-18 hydrocarbyl with optionally .gtoreq.1 heteroatoms, bonded to the steroid by a C; R2 = C1-8 hydrocarbyl; X = rest of 5- or 6-membered (substituted) (unsatd.) ring; A:C = oxo (free or in ketal), CH(OH), CH(OR3), CH(O2CR3), etc.; R3 = C1-8 alkyl, C7-15 aralkyl; B and C together form a double bond or epoxide bridge] and their acid and base addn. salts, are used for making pharmaceuticals for stimulating ovulation, e.g. in cows. The compds. of the invention are preferably used following treatment with progesterone or a progesteronimetic, e.g. 3-oxo-17.alpha.-allyl-17.beta.-hydroxyestra-4,9,11-triene (II). Thus, heifer cows were 1st administered II for 17 days; on the day following the last administration, the animals were injected with 17.beta.-hydroxy-11.beta.-(4-dimethylaminophenyl)-17.alpha.-(prop-1-ynyl)estra-4,9-dien-3-one. All of the heifers came to heat after a very short delay period, and LH levels rose very rapidly. Prepn. of 12 anti-progesteronimetics is presented.

MSTR 1E




L9 ANSWER 10 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 115:9125 MARPAT
 TITLE: Preparation of omega-[(3-oxoestra-4,9-dien-11.beta.-yl)phenylamino]alkanoates as antiglucocorticoids
 INVENTOR(S): Moguilevsky, Martine; Nedelec, Lucien; Nique, Francois; Philibert, Daniel
 PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
 SOURCE: Eur. Pat. Appl., 33 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 414606	A2	19910227	EP 1990-402328	19900822
EP 414606	A3	19910724		
EP 414606	B1	19941102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2651233	A1	19910301	FR 1989-11173	19890823
FR 2651233	B1	19911213		
CA 2022648	AA	19910224	CA 1990-2022648	19900803
ZA 9006341	A	19911030	ZA 1990-6341	19900810
US 5166146	A	19921124	US 1990-568597	19900816
JP 03090097	A2	19910416	JP 1990-217281	19900820
JP 3026997	B2	20000327		
IL 95451	A1	19950731	IL 1990-95451	19900821
AU 9061189	A1	19910228	AU 1990-61189	19900822
AU 634569	B2	19930225		
HU 54706	A2	19910328	HU 1990-5275	19900822
HU 208154	B	19930830		
ES 2063313	T3	19950101	ES 1990-402328	19900822
CN 1051362	A	19910515	CN 1990-107161	19900823
CN 1033808	B	19970115		
RU 2041236	C1	19950809	RU 1992-5011511	19920518
			FR 1989-11173	19890823

PRIORITY APPLN. INFO.: CASREACT 115:9125
 OTHER SOURCE(S):
 AB The title compds. [I: R1 = aliph. hydrocarbyl; R2 = H, (un)substituted alkyl; R5, R6 = H, alkyl; X = atoms to complete an (un)substituted 5- or 6-membered ring; Z = (un)saturated CO2H; n = 1-6] were prepd. Thus, aminophenylestradienone II (R = R5 = R6 = H) was condensed with BrCH2CO2Me to give, after sapon., I (R = CH2CO2Na, R5 = R6 = H) which at 10-6M in vitro gave 82% inhibition of uridine incorporation into rat thymocytes.

MSTR 1A



G3 = phenylene
 G4 = NH
 G9 = 39-18 37-17

L9 ANSWER 9 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)

G1 = 85
 PgC6H4G10
 G10 = NMe2
 G12 = 96
 G6(O)-G14
 G14 = 98
 H2O-G15
 G15 = OH
 G5 + G6 = O
 DER: or acid or base addition salts
 MPL: claim 2
 NTE: oxo formed by G5 and G6 may be protected as a ketal

L9 ANSWER 10 OF 14 MARPAT COPYRIGHT 2004 ACS on STN (Continued)

G16-G10-G12
 G10 = (1-2) 45
 G11-G12
 G13 = 53
 G6(O)-CH2-OH
 G16 = 68
 G13-G13
 MPL: claim 1

L9 ANSWER 11 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

114:229227 MARPAT

TITLE:

Preparation of 19-nor 3-oxo steroids with an amine substituted 17-chain as anti-inflammatories: their use as medicines and pharmaceutical composition containing them

INVENTOR(S):

Claussner, Andre; Leclaire, Jacques; Nedelec, Lucien; Philibert, Daniel

PATENT ASSIGNEE(S):

Roussel-UCLAF, Fr.

SOURCE:

Eur. Pat. Appl., 29 pp.

DOCUMENT TYPE:

CODEN: EPXXDW

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 389370	A1	19900926	EP 1990-400784	19900322
EP 389370	B1	19940427		
R: CH, DE, FR, GB, IT, LI, NL				
FR 2644789	A1	19900928	FR 1989-3742	19890322
FR 2644789	B1	19950203		
JP 02273693	A2	19901108	JP 1990-68508	19900320
JP 2848907	B2	19990120		
US 5108996	A	19920428	US 1990-497562	19900321
			FR 1989-3742	19890322


PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

CASREACT 114:229227

AB The title compds. [I: R1, R2 = H, Me; R11 = (poly)(hetero)hydrocarbyl; one of R17 and R18 is OH or acyloxy and the other is Q; Z = alkylene, alkenylene, alkyneylene; P = (substituted) pyrimidinyl, pyridyl] were prepd. via reacting the halo derivs. II or III (X = halo) with the appropriate pyrimidinyl or pyridine deriv. IV. Reaction of estradienone V (R3 = 3-bromo-1-propynyl, R4 = OH) (prepn. given) was reacted with 2,4-bis(1-pyrrolidinyl)-6-(1-piperazinyl)pyrimidine (prepn. given) in acetone contg. K2CO3 at ambient temp. for 2 h to give V (R3 = 3-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-1-propynyl; R4 = OH). At 5 times. 10-4 M this inhibited in vitro the formation of malonyldialdehyde, a measure of lipid peroxidn., in rat brain homogenate by approx. 47.5%.

MSTR 3



G2 = 107

L9 ANSWER 12 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

113:115677 MARPAT

TITLE:

Preparation of androstane derivatives as drugs

INVENTOR(S):

Scholz, Stefan; Neef, Guenter; Ottow, Eckhard; Elger, Walter; Beier, Sybille; Chwalisz, Krzysztof

PATENT ASSIGNEE(S):

Schering A.-G., Germany

SOURCE:

Eur. Pat. Appl., 38 pp.

DOCUMENT TYPE:

CODEN: EPXXDW

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 360369	A1	19900328	EP 1989-250040	19890920
EP 360369	B1	19950503		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3832303	A1	19900412	DE 1988-3832303	19890920
IL 91672	A1	19941229	IL 1989-91672	19890918
WO 9003385	A1	19900405	WO 1989-EP1090	19890920
W: AU, DK, FI, HU, JP, NO, US				
AU 8943049	A1	19900418	AU 1989-43049	19890920
AU 640616	B2	19930902		
ZA 8907191	A	19901031	ZA 1989-7191	19890920
DD 284682	A5	19901121	DD 1989-332836	19890920
HU 56851	A2	19911028	HU 1989-5541	19890920
HU 208151	B	19930930		
JP 04501712	T2	19920326	JP 1989-509963	19890920
JP 2760870	B2	19980604		
AT 122052	E	19950515	AT 1989-250040	19890920
ES 2074073	T3	19950901	ES 1989-250040	19890920
NO 9101102	A	19910319	NO 1991-1102	19910319
DK 9100504	A	19910320	DK 1991-504	19910320
US 5244886	A	19930914	US 1991-663819	19910320
NO 9104772	A	19910319	NO 1991-4772	19911204
			DE 1988-3832303	19890920
			WO 1989-EP1090	19890920
			NO 1991-1102	19910319

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):


CASREACT 113:115677

AB The title compds. [I: Z = O, hydroxyimino; LM = bond, or L = H and M = .alpha.-OH; AB = bond and D = H and R1 = heteroaryl; or A = H and BD = CH2 and Z = H2; R3, R4 = tetrahydropyranyloxyalkyl, tetrahydropyranyloxyalkenyl, etc.], useful as antiglucoocorticoids, neoplasm inhibitors (esp. for breast cancer), progestogen inhibitors, and antiproliferative agents, were prepd. 3-(Tetrahydropyranyloxy)-1-propyne was lithiated with BuLi in THF-hexane and the product treated with 14.beta.-androstane-17-one II (R3R4 = O) (prepn. given) to give II (R3 = Q, R4 = OH) treated with 4N HCl to give I [R1 = OMe, R2 = Me, R3 = (CH2)3OH, BD = CH2, LM = bond, Z = O, A = H] (III). III had higher affinity for the gestagen receptor than the known EP-A 0277676 [11.beta.-[4-(dimethylamino)phenyl]-17.alpha.-hydroxy-17-(3-hydroxypropyl)-14.beta.-estra-4,9-dien-3-one].

MSTR 1A

L9 ANSWER 11 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

(Continued)



G4

= OH

G14

= piperazino

MPL:


claim 13

NTE:

the alkylamino and dialkylamino groups in G11 may be interrupted by oxygen, sulfur, or nitrogen

L9 ANSWER 12 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

(Continued)



G1


= O

G4

= Hy<EC (1-2) Q (-2) N (-1) O (-1) S (3-4) C (0) OTHERQ, AN (0) N, AR (1-), BD (2) DE, RC (1), RS (1) ES> (SO (1-)) G8)

G20

= 45



G28

= alkyl<(1-4)>

G29

= Me

MPL:

claim 1

L9 ANSWER 13 OF 14 MARPAT COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 112:235680 MARPAT
 TITLE: Preparation of 13-alkyl-11.beta.-phenylgonanes as
 antigestagens and antiglucocorticoids
 INVENTOR(S): Scholz, Stefan; Ottow, Eckhard; Neef, Guenter; Elger,
 Walter; Beier, Sybille; Chwalisz, Krzysztof
 PATENT ASSIGNEE(S): Schering A.-G., Germany
 SOURCE: Ger. Offen., 22 pp.
 CODEN: GWKXEX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3822770	A1	19900104	DE 1988-3822770	19880701
IL 90826	A1	19940624	IL 1989-90826	19890630
CA 1334668	A1	19950307	CA 1989-604596	19890630
EP 349481	A1	19900103	EP 1989-730155	19890703
EP 349481	B1	19951102		
WO 9000174	A1	19900111	WO 1989-DE443	19890703
AU 8938568	A1	19900123	AU 1989-38568	19890703
AU 644060	B2	19931202		
ZA 8905058	A	19900425	ZA 1989-5058	19890703
DD 287511	A5	19910228	DD 1989-330342	19890703
HU 56114	A2	19910729	HU 1989-4130	19890703
HU 208021	B	19930728		
DD 295638	A5	19911107	DD 1989-341722	19890703
JP 03505727	T2	19911212	JP 1989-507188	19890703
JP 2956776	B2	19991004		
US 5273971	A	19931228	US 1989-374809	19890703
AT 129717	E	19951115	AT 1989-730155	19890703
ES 2080079	T3	19960201	ES 1989-730155	19890703
NO 9005609	A	19910228	NO 1990-5609	19901227
NO 180451	B	19970113		
NO 180451	C	19970423		
US 5446036	A	19950829	US 1993-144474	19931102
FI 9504856	A	19951012	FI 1995-4856	19951012
NO 9600829	A	19910228	NO 1996-829	19960229
			DE 1988-3822770	19880701
			US 1989-374809	19890703
			WO 1989-DE443	19890703
			NO 1990-5609	19901227
			FI 1990-6441	19901228

PRIORITY APPLN. INFO.:

AB The title compds. [I; R1 = heterocyclyl, cycloalkyl, cycloalkenyl, alkenyl, etc.; R2 = .alpha.-, .beta.-Me, -Et; R3, R4 = alkoxy, acyl, oxofuryl, alkynyl, etc.; Z = O, NOH], antigestagens and antiglucocorticoids useful for induction of abortion, were prepd. via Grignard reaction of the corresponding 5.alpha.,10.alpha.-epoxy-9(11) unsatd. steroids with p-R1C6H4X (X = halo). Grignard reaction of epoxy steroid II (prepn. given) with p-CH2:CHC6H4X (X = Br, Iodo) gave I [R1 = CH2:CH, R2 = .beta.-Me, R3 = OH, R4 = C.tplbond.CMe, Z = OCH2CMe2CH2O], which was hydrolyzed to give I [Z = O, R1-R4 same as above]. This at 3.0 mg s.c./day induced abortion in 100% of rats tested.

L9 ANSWER 14 OF 14 MARPAT COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 110:213172 MARPAT
 TITLE: 13(Alpha)-alkylgonanes, their production, and
 pharmaceutical preparations containing same
 INVENTOR(S): Neef, Guenter; Wiechert, Rudolf; Beier, Sybille;
 Elger, Walter; Henderson, David
 PATENT ASSIGNEE(S): Schering A.-G., Fed. Rep. Ger.
 SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 621,308.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4780461	A	19881025	US 1985-810148	19851218
DE 3321826	A1	19841220	DE 1983-3321826	19830615
DE 3413036	A1	19851017	DE 1984-3413036	19840404
DE 3446661	A1	19860619	DE 1984-3446661	19841218
			DE 1983-3321826	19830615
			DE 1984-3413036	19840404
			US 1984-621308	19840615
			DE 1984-3446661	19841218

OTHER SOURCE(S):

CASREACT 110:213172
 AB 13.alpha.-Alkylgonanes [I; R = C1-4 acyl; X = O, NOH; II; R1 = amino; R2 = H, Me, Et; R3 = (substituted) alkyl; R4 = OH, alkoxy, alkanoyloxy; or R3R4 = O; R5 = H, alkyl; III; Z = CH2CH2, CH2CMe2CH2], having antigestagenic activity and useful as postcoital contraceptives, or for triggering abortion and menstruation (no data), are prepd. via photochem. epimerization of the 13.beta.-gonanes IV. 11.beta.-(4-Dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-hydroxypropyl)-4,9-gonadien-3-one (V) was acetylated with Ac2O in pyridine to give 11.beta.-(4-dimethylaminomethyl)-17.alpha.-hydroxy-13.alpha.-methyl-17.beta.-(3-acetoxypentyl)-4,9-gonadien-3-one. A tablet was formulated contg. V 10.0, lactose 140.0, corn starch 69.5, polyvinylpyrrolidone 25 2.5, Aerosil 2.0, and Mg stearate 0.5 mg.

MSTR 2



=> d his

(FILE 'HOME' ENTERED AT 08:10:41 ON 24 MAR 2004)

FILE 'REGISTRY' ENTERED AT 08:10:56 ON 24 MAR 2004

L1 STRUCTURE UPLOADED

L2 9 S L1

L3 163 S L1 FULL

FILE 'CAPLUS' ENTERED AT 08:11:56 ON 24 MAR 2004

L4 7 S L3

FILE 'BEILSTEIN' ENTERED AT 08:17:49 ON 24 MAR 2004

L5 0 S L1 FULL

FILE 'USPATFULL' ENTERED AT 08:18:24 ON 24 MAR 2004

L6 4 S L3 FULL

L7 0 S L6 NOT L4

FILE 'MARPAT' ENTERED AT 08:18:45 ON 24 MAR 2004

L8 19 S L3 FULL

L9 14 S L8 NOT L4